A unique model for treating chronic hepatitis c in patients with psychiatric disorders, substance abuse, and/or housing instability

Journal of Addiction Medicine

Volumn 7, Issue 5, 2013, Pages 320-324

  Ho, Cheryl J ^a   Preston, Charles ^a   Fredericks, Kim ^a   Doorley, Sara L ^a   Kramer, Richard J ^a   Kwan, Lawrence ^a   Kamal, Ahmad ^a  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Hepatitis C; Homeless persons; Injection drug use; Interdisciplinary communication; Mental illness; Patient centered care

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEPATITIS C; HOMELESSNESS; HUMAN; MALE; MENTAL DISEASE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; CALIFORNIA; COMORBIDITY; DRUG MONITORING; FEMALE; HEPATITIS C, CHRONIC; HOMELESS PERSONS; HUMANS; INTERDISCIPLINARY COMMUNICATION; MALE; MEDICATION ADHERENCE; MENTAL DISORDERS; MIDDLE AGED; MODELS, ORGANIZATIONAL; PATIENT-CENTERED CARE; PILOT PROJECTS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84887950723     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31829b1a6c     Document Type: Article

References (23)

1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-714
2. Charlebois A, Lee L, Cooper E, et al. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients. J Viral Hepat 2012;19(12): 836-842
3. Cheung RC, Hanson AK, Maganti K, et al. Viral hepatitis and other infectious diseases in a homeless population. J Clin Gastroenterol 2002;34(4): 476-480
4. Derogatis LR. BSI Brief Symptom Inventory: Administration, Scoring, and Procedure Manual (4th Ed.). Minneapolis, MN: National Computer Systems. San Antonio, TX: Pearson, 1993
5. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001;345(3): 211-215
6. Evon DM, Verma A, Dougherty KA, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007;52(11):3251-3258
7. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347(13): 975-982
8. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010;22(3):270-277
9. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004;140(5):346-355
10. Knott A, Dieperink E, Willenbring ML, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006;101(10):2254-2262
11. Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis 2005;40 (suppl 5):S339-S345
12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358(9286): 958-965
13. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378(9791):571-583
14. Nyamathi AM, Dixon EL, Robbins W, et al. Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med 2002;17(2):134-143
15. Robaeys G, Van Vlierberghe H, Matheï C, et al. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparisonwith other infection causes. Eur J Gastroenterol Hepatol 2006;18(2):159-166
16. Schaefer M, Hinzpeter A, Mohmand A, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferonalpha and ribavirin: response and psychiatric side effects. Hepatology 2007;46(4):991-998
17. Schaefer M, Sarkar R, Knop V, et al. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial. Ann Intern Med 2012;157(2):94-103
18. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-451
19. Stein MR, Soloway IJ, Jefferson KS, et al. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat 2012;43(4):424-432
20. Sylvestre DL. Treating hepatitis C virus infection in active substance users. Clin Infect Dis 2005;40(suppl 5):S321-S324
21. SylvestreDL, Litwin AH, Clements BJ, et al. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat 2005;29(3):159-165
22. Williams IT, Bell BP, Kuhnert W, et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 2011;171(3):242-248
23. Zickmund S, Hillis SL, Barnett MJ, et al. Hepatitis C virus-infected patients report communication problems with physicians. Hepatology 2004;39(4):999-1007